Bora Pharmaceuticals Co., Ltd. announced that its Board of Directors has approved the acquisition of US-based Pyros Pharmaceuticals, Inc. ("Pyros"), a specialty pharmaceutical company developing treatments for rare diseases.
Anixa Biosciences, Inc. "Anixa" or the a biotechnology company focused on the treatment and prevention of cancer, announced that it has administered the second dose of its CAR-T therapy to an individual patient.This follows a positive response after the initial treatment in the ongoing Phase 1 clinical trial of its chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted in collaboration with Moffitt Cancer Center.
Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio company, announced that it has received FDA 510(k) clearance to market RejuvaKnee™, a minimally invasive collagen-based meniscal implant indicated for use in the reinforcement and repair of soft tissue injuries of the meniscus.
BioIntelliSense, a continuous health monitoring and clinical intelligence company, announces FDA clearance of the rechargeable BioButton® Multi-Patient wearable and BioDashboard™ system to cost-effectively grow and scale hospital virtual care programs.
Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, announced the release of its new Chip-R1™ Rigid Chip, designed to minimize drug absorption and enhance biological modeling. Constructed using low-drug-absorbing plastics, Chip-R1 builds upon the core microfluidic design of Organ-Chips, offering researchers greater precision in predicting human drug responses.
Spineology Inc., the pioneer of Conform and Expand™ Technology, unveiled a new brand and visual identity, logo, and product positioning as part of an extensive rebranding initiative. This new brand defines Spineology’s flagship interbody fusion portfolio, OptiMesh®, and establishes it within a category of its own.
Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced an expansion in capabilities through the licensing of ATUM's innovative miFuc™ platform designed for expression of recombinant proteins containing afucosylated glycans.
Axion BioSystems and STEMCELL Technologies are pleased to announce a strategic partnership that will enable STEMCELL to sell Axion’s state-of-the-art Maestro Pro™ and Maestro Edge™ multielectrode array (MEA) systems within North America and Europe. The industry-leading Maestro MEA systems will also continue to be available for purchase worldwide directly from Axion BioSystems.
Novavax, Inc. a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the U.S.
Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and commercial-scale cell therapy manufacturing, announced the commissioning of the first cGMP Cell Shuttle™ at the IDMO Smart Factory in Bridgewater, New Jersey. This marks an important milestone on the way to a fully fitted facility, which will be capable of producing up to 40,000 standard CAR-T cell therapy doses per year, or up to 100,000 doses of novel, two-day process CAR-T cell therapies.